CAS
LCTX icon

Coppell Advisory Solutions’s Lineage Cell Therapeutics LCTX Stock Holding History

Coppell Advisory Solutions’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-63
Closed -$31 – 1173
2024
Q4 		$31 Hold
63
– – ﹤0.01% 1951
2024
Q3 		$58 Hold
63
– – ﹤0.01% 1829
2024
Q2 		$63 Buy
+63
New +$70 ﹤0.01% 1748
2023
Q4 		$69 Sell
63
-99
-61% -$108 ﹤0.01% 1665
2023
Q3 		$190 Buy
162
+68
+72% +$93 ﹤0.01% 1116
2023
Q2 		$132 Buy
+94
New +$130 ﹤0.01% 1360
2023
Q1 		– Sell
-162
Closed -$190 – 690
2022
Q4 		$190 Buy
+162
New +$204 ﹤0.01% 1118

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Coppell Advisory Solutions's LCTX Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Lineage Cell Therapeutics (LCTX) in Q1 2025, closing a stake of 63 shares — an estimated $31 sold.

Coppell Advisory Solutions first reported a position in LCTX in Q4 2022 and held it in 7 quarters. The position peaked at $190 in Q3 2023. 127 funds tracked by Wall St. Rank hold LCTX as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Lineage Cell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 63 Lineage Cell Therapeutics shares in Q1 2025, an estimated $31.
  • Coppell Advisory Solutions first reported a position in Lineage Cell Therapeutics in Q4 2022 and held it in 7 quarters.
  • Coppell Advisory Solutions's Lineage Cell Therapeutics position peaked at $190 in Q3 2023.
  • 127 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.